Biologic Differences Between Vasodilator Prostaglandins and Medullipin I
| Autor: | Byers Lw, B. Brooks, E. Eric Muirhead |
|---|---|
| Rok vydání: | 1992 |
| Předmět: |
medicine.medical_specialty
Hepatic ablation Vasodilator Agents Prostaglandin Blood Pressure Vasodilation Dinoprostone chemistry.chemical_compound Rats Inbred SHR Internal medicine Animals Medicine Antihypertensive Agents Skf 525a Medullipin I Prostaglandins A Kidney urogenital system business.industry General Medicine Epoprostenol Lipids Rats Endocrinology medicine.anatomical_structure chemistry Prostaglandins lipids (amino acids peptides and proteins) business circulatory and respiratory physiology |
| Zdroj: | The American Journal of the Medical Sciences. 303:86-89 |
| ISSN: | 0002-9629 |
| DOI: | 10.1097/00000441-199202000-00004 |
| Popis: | Vasodepressor prostaglandins (PGs), PGE 2 , PGI 2 , and medullipin I (Med I) are synthesized in the kidney. These vasodilator substances are thought to be involved in the antihypertensive function of the kidney. At issue is whether there are biologic differences between the vasodilator PGs and Med I. Two separate studies have shown that Med I’s vasodepressor action is inhibited by four procedures: mixing with Tween 20; treatment with n-butyl boronic acid; treatment of the assay animal with SKF 525A, an inhibitor of cytochrome P-450; and removing the liver from the circulation. These same procedures were applied to the vasodilator PGs. All four failed to inhibit the vasodepressor action of the PG’s. It is concluded that Med I nd vasodilator PGs of the kidney are separate and distinct biologic entities. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|